Risk Of Developing Liver Cancer After HCV Treatment

Sunday, April 15, 2018

Long term follow up of HCV pts with F2-F3 fibrosis who had achieved SVR with DAA therapy

Shared on Twitter today by @HenryEChang


Liver-related & HCC events were rare after up to 144 weeks of follow-up in patients with F2-F3 fibrosis who had achieved SVR with DAA therapy: Results from the Gilead Sciences SVR Registry


No comments:

Post a Comment